Plavix, which has brought Bristol-Myers Squibb (BMY) $42.8B over 15 years, loses its patent protection today. In total, 19 drugs are set to relinquish such protection in 2012 - dubbed the year of "pharmageddon" - costing the industry $38.5B. BMY is now pinning its hopes on the yet-to-be-approved blood thinner Eliquis to make up for Plavix
Market Data 
Markets 
AI
